Targeted radionuclide therapy of painful bone metastases: past developments, current status, recent advances and future directions

A Dash, T Das, FFR Knapp - Current medicinal chemistry, 2020 - ingentaconnect.com
Bone pain arising from secondary skeletal malignancy constitutes one of the most common
types of chronic pain among patients with cancer which can lead to rapid deterioration of the …

[HTML][HTML] PEGylated liposome-encapsulated rhenium-188 radiopharmaceutical inhibits proliferation and epithelial–mesenchymal transition of human head and neck …

CY Chang, CC Chen, LT Lin, CH Chang, LC Chen… - Cell death …, 2018 - nature.com
Human head and neck squamous cell carcinoma (HNSCC) is usually treated with
chemoradiotherapy, but the therapeutic efficacy could be hampered by intrinsic …

Appraisement of 186/188Re-HEDP, a new compositional radiopharmaceutical

Z Pourhabib, H Ranjbar, A Bahrami Samani… - … of Radioanalytical and …, 2019 - Springer
Undoubtedly radionuclide therapy is the next phase of nuclear medicine development. 188
Re-HEDP and 186 Re-HEDP are therapeutic radiopharmaceuticals which have been used …

[HTML][HTML] Preparation and biological evaluation of 186/188Re-HEDP as a new cocktail radiopharmaceutical for palliative treatment of osseous metastases in wild type …

Z Pourhabib, H Ranjbar, A Bahrami Samani… - Iranian Journal of …, 2021 - irjnm.tums.ac.ir
Introduction: The palliative care in patients with bone metastasis includes variety of
techniques such as conventional analgesics, surgery, external beam radiotherapy, hormone …

Therapeutic radiopharmaceuticals for bone pain palliation

FF Knapp, A Dash, FF Knapp, A Dash - Radiopharmaceuticals for Therapy, 2016 - Springer
Primary tumors often metastasize when tumor cells migrate via the blood supply or
lymphatics to seed other sites for tumor progression. Particularly in prostate, breast, and lung …